Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma

Background: The present study aimed to assess the efficacy and safety of lenvatinib and verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) in real-world practice, primarily focusing on the population that w...

Descripció completa

Dades bibliogràfiques

Autors principals:	Susumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, Masamichi Obu, Masanori Inoue, Norio Itokawa, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Ryosaku Azemoto, Ei Itobayashi, Masanori Atsukawa, Nobuyuki Sugiura, Hideaki Mizumoto, Keisuke Koroki, Kengo Kanayama, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Format:	Artigo
Idioma:	Inglês
Publicat:	Karger Publishers 2020-05-01
Col·lecció:	Liver Cancer
Matèries:	hepatocellular carcinoma lenvatinib reflect trial
Accés en línia:	https://www.karger.com/Article/FullText/507022
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!